Maze Therapeutics (MAZE) Share-based Compensation (2024 - 2026)
Maze Therapeutics (MAZE) posted Share-based Compensation of $58.0 million for Q1 2026, up 855.05% sequentially from $6.1 million in Q4 2025, and up 1697.89% YoY from $3.2 million in Q1 2025.
Maze Therapeutics (MAZE) Share-based Compensation (2024 - 2026) Analysis & Trends
Maze Therapeutics has reported Share-based Compensation for 3 years, with the latest figure at $58.0 million in Q1 2026.
- Quarterly Share-based Compensation rose 1697.89% year-over-year to $58.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $58.0 million (up 449.14% YoY) and the FY2025 annual result came in at $28.4 million, down 5.33% from the prior year.
- Share-based Compensation climbed to $58.0 million in Q1 2026 per MAZE's latest filing, from $6.1 million in the prior quarter.
- Over five years, Share-based Compensation peaked at $58.0 million in Q1 2026 and troughed at $2.1 million in Q2 2024.
- A 3-year average of $12.3 million and a median of $3.2 million in 2025 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2025 and 2026: Share-based Compensation jumped 39.65% in 2025, then soared 1697.89% in 2026.
- Over 3 years, Share-based Compensation stood at $2.9 million in 2024, then jumped by 113.01% to $6.1 million in 2025, then soared by 855.05% to $58.0 million in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered $58.0 million, $6.1 million, and $30.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Maze Therapeutics | 1.51 Bn | 1.51 Bn | - | 9.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.19 Mn |
| Jun 30, 2026 | 9.19 Mn |
| Mar 31, 2026 | 58.00 Mn |
| Mar 31, 2026 | 58.00 Mn |
| Dec 31, 2025 | 6.07 Mn |
| Dec 31, 2025 | 6.07 Mn |
| Sep 30, 2025 | 30.60 Mn |
| Sep 30, 2025 | 30.60 Mn |
| Jun 30, 2025 | 3.24 Mn |
| Jun 30, 2025 | 3.24 Mn |
| Mar 31, 2025 | 3.23 Mn |
| Mar 31, 2025 | 3.23 Mn |
| Dec 31, 2024 | 2.85 Mn |
| Dec 31, 2024 | 2.85 Mn |
| Sep 30, 2024 | 2.34 Mn |
| Sep 30, 2024 | 2.34 Mn |
| Jun 30, 2024 | 2.14 Mn |
| Jun 30, 2024 | 2.14 Mn |
| Mar 31, 2024 | 2.31 Mn |
| Mar 31, 2024 | 2.31 Mn |